Skip to main content

Table 1 Patients clinical and demographic characteristics based on duration of SARS-CoV-2 RNA persistence in the nasopharynx

From: Persistence of SARS-CoV-2 RNA in the nasopharyngeal, blood, urine, and stool samples of patients with COVID-19: a hospital-based longitudinal study

 

All patient

Duration of SARS-CoV-2 RNA persistence in the nasopharynx

P*

≤ 7 days after admission

7–13 days after admission

≥ 14 days after admission

Count

100

46 (46%)

43 (43%)

11 (11%)

 

Age, years

    

0.878

 < 50

39

17 (43.6%)

18 (46.2%)

4 (10.3%)

 

 ≥ 50

61

29 (47.5%)

25 (41%)

7 (11.5%)

 

Gender

    

0.479

 Male

60

27 (45%)

28 (46.7%)

5 (8.3%)

 

 Female

40

19 (47.5%)

15 (37.5%)

6 (15%)

 

Marital status

    

0.730

 Single

16

7 (43.8%)

8 (50%)

1 (6.2%)

 

 Married

84

39 (46.4%)

35 (41.7%)

10 (11.9%)

 

Job

    

0.598

 No

32

14 (43.8%)

13 (40.6%)

5 (15.6%)

 

 Yes

68

32 (47.1%)

30 (44.1%)

6 (8.8%)

 

Education

    

0.441

 Less than diploma

63

26 (41.3%)

29 (46%)

8 (12.7%)

 

 Diploma and more

37

20 (54.1%)

14 (37.8%)

3 (8.1%)

 

Residency

    

0.195

 Urban

85

40 (47.1%)

34 (40%)

11 (12.9%)

 

 Rural

15

6 (40%)

9 (60%)

0 (0%)

 

Socioeconomic status

    

0.280

 Low

82

37 (45.1%)

35 (42.7%)

10 (12.2%)

 

 Moderate to high

18

9 (50%)

8 (44.4%)

1 (0.06%)

 

Underling disease

    

0.945

 No

50

23 (46%)

21 (42%)

6 (12%)

 

 Yes

50

23 (46%)

22 (44%)

5 (10%)

 

O2 saturation

93.84 ± 4.33

93.85 ± 4.03

93.88 ± 3.98

93.64 ± 6.80

0.986

Hospital treatment plana

    

0.477

 Hydroxychloroquine

5

2 (40%)

2 (40%)

1 (20%)

 

 Local treatment b

62

32 (51.6%)

25 (40.3%)

5 (8.1%)

 

 Anti-viral c

18

5 (27.8%)

11 (61.1%)

2 (11.1%)

 

 Interferon

15

7 (46.7%)

5 (33.3%)

3 (20%)

 

COVID-19 symptoms

     

Dyspnea

    

0.122

 No

44

18 (40.9%)

18 (40.9%)

8 (18.2%)

 

 Yes

56

28 (50%)

25 (44.6%)

3 (5.4%)

 

Sore throat

    

0.586

 No

78

38 (48.7%)

32 (41%)

8 (10.3%)

 

 Yes

22

8 (36.4%)

11 (50%)

3 (13.6%)

 

Muscular pain

    

0.152

 No

82

37 (45.1%)

38 (46.3%)

7 (8.5%)

 

 Yes

18

9 (50%)

5 (27.8%)

4 (22.2%)

 

Headache

    

0.470

 No

76

34 (44.7%)

32 (42.1%)

10 (13.2%)

 

 Yes

24

12 (50%)

11 (45.8%)

1 (4.2%)

 

Diarrhea

    

0.795

 No

84

38 (45.2%)

36 (42.9%)

10 (11.9%)

 

 Yes

16

8 (50%)

7 (43.8%)

1 (6.2%)

 

Fever

    

0.991

 No

19

9 (47.4%)

8 (42.1%)

2 (10.5%)

 

 Yes

81

37 (45.7%)

35 (43.2%)

9 (11.1%)

 

Cough

    

0.249

 No

30

14 (46.7%)

15 (50%)

1 (3.3%)

 

 Yes

70

32 (45.7%)

28 (40%)

10 (14.3%)

 

Weakness

    

0.550

 No

93

43 (46.2%)

39 (41.9%)

11 (11.8%)

 

 Yes

7

3 (42.9%)

4 (57.1%)

0 (0%)

 

Nausea and vomiting

    

0.145

 No

79

40 (50.6%)

32 (40.5%)

7 (8.9%)

 

 Yes

21

6 (28.6%)

11 (52.4%)

4 (19%)

 

Chills

    

0.886

 No

21

9 (42.9%)

10 (47.6%)

2 (9.5%)

 

 Yes

79

37 (46.8%)

33 (41.8%)

9 (11.4%)

 

Inflammatory markers

     

 WBC, cell/mL

7.41 ± 3.95

7.15 ± 3.42

7.96 ± 4.63

6.37 ± 3.05

0.415

 ESR, mm/h

53.38 ± 28.11

50.78 ± 29.64

55.88 ± 26.42

54.45 ± 29.66

0.692

CRP, mg/L

     

 < 12

24

11 (23.9%)

11 (25.6%)

2 (18.2%)

0.473

 12–20

16

6 (13%)

9 (20.9%)

4 (36.4%)

 

 > 20

57

29 (63%)

23 (53.5%)

5 (45.5%)

 

Ct value(mean ± SD)

29.67 ± 4.69

29.98 ± 4.45

29.33 ± 5.25

29.73 ± 3.47

0.809

Nasopharyngeal viral load at admission, n (%)

    

0.464

 High (Ct < 20)

1

0 (0%)

1 (100%)

0 (0%)

 

 Medium (Ct 20–29.9)

47

19 (40.4%)

22 (46.8%)

6 (12.8%)

 

 Low (Ct ≥ 30)

52

27 (51.9%)

20 (38.5%)

5 (9.6%)

 
  1. Continuous variables are presented as mean ± SD
  2. COVID-19 Coronavirus disease 2019, SARS-CoV-2 RNA sever acute respiratory syndrome coronavirous2, WBC Wight blood cells, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, Ct value cycle threshold value
  3. *Statistical significance based on the Chi-square or ANOVA test, Pearson correlation coefficient
  4. aAll of the patients received corticosteroids
  5. bIncluding diphenhydramine, acetaminophen, zinc, vitamin C, famotidine
  6. cIncluding lopinavir, Sovodak (Sofosbuvir at 400 mg and daclatasvir at 60 mg, Remdesivir)
Back to article page

Virology Journal

ISSN: 1743-422X